Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.

@article{Berghoff2015TumourinfiltratingLA,
  title={Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.},
  author={Anna S. Berghoff and Gerda Ricken and Georg Widhalm and Orsolya Rajky and Karin Dieckmann and Peter Birner and Rupert Bartsch and Christoph Hoeller and Matthias Preusser},
  journal={Histopathology},
  year={2015},
  volume={66 2},
  pages={
          289-99
        }
}
AIMS In this study we aimed to characterize immune infiltrates and expression of programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) in a series of melanoma BM to provide a basis for experimental therapy using immune checkpoint inhibitors. METHODS AND RESULTS We investigated expression of PD-1, PD-L1, CD3, CD8, CD45RO, forkhead box protein 3 (FoxP3), CD20 and BRAF V600E by immunohistochemistry in melanoma BM samples. Forty-three specimens [27 of which (62.8%) were BRAF V600E… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 53 CITATIONS, ESTIMATED 52% COVERAGE

Immune Checkpoint Blockade – How Does It Work in Brain Metastases?

VIEW 3 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis.

VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2014
2020

CITATION STATISTICS

  • 4 Highly Influenced Citations

  • Averaged 10 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

VIEW 12 EXCERPTS
HIGHLY INFLUENTIAL

Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases.

VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

VIEW 2 EXCERPTS

Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.

VIEW 1 EXCERPT

Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

VIEW 1 EXCERPT